KeViRx, Inc.

KeViRx, Inc. is a biotechnology research company focused on developing innovative small molecule drugs. Headquartered in Charlottesville, VA, KeViRx, Inc. is dedicated to addressing microvascular leakage and inflammation, which are fundamental pathologies underlying various diseases, including cancer and respiratory ailments. The primary address for KeViRx, Inc. is Charlottesville, VA 22904, US.

KeViRx, Inc. is advancing its lead asset, KVX-053, through IND-enabling studies for pulmonary microvascular leakage and inflammation during acute lung injury. KVX-053 exhibits potent anti-inflammatory and immunomodulatory effects, demonstrating promising results in preclinical models by reducing lung injury scoring and improving lung function. KeViRx, Inc. is committed to pioneering advancements in pharmaceutical research to improve patient outcomes.

KeViRx, Inc. is poised for continued growth and success in the biotechnology sector. We invite the manager of KeViRx, Inc. to create a customized and exclusive company showcase and product listing on our platform to further enhance your market presence and commercial development.